Cooperative relationship between pharmaceutical companies, academia, and media explains sharp decrease in frequency of pulmonary complications after bortezomib in Japan.
Narimatsu
Hiroto
H
Hori
Akiko
A
Matsumura
Tomoko
T
Kodama
Yuko
Y
Takita
Morihito
M
Kishi
Yukiko
Y
Hamaki
Tamae
T
Yuji
Koichiro
K
Tanaka
Yuji
Y
Komatsu
Tsunehiko
T
Kami
Masahiro
M
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D003299:Cooperative Behavior; D004345:Drug Industry; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D033183:Interdisciplinary Communication; D020407:Internet; D007564:Japan; D008171:Lung Diseases / Q000139:chemically induced / Q000517:prevention & control*; D008402:Mass Media; D008503:Medical Staff; D009101:Multiple Myeloma / Q000188:drug therapy*; D009524:Newspapers as Topic; D018579:Patient Selection; D010506:Periodicals as Topic; D017410:Practice Guidelines as Topic; D011719:Pyrazines / Q000009:adverse effects*; D018570:Risk Assessment; D012955:Societies, Medical
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib